Vaccines are invaluable
because they establish or improve immunity to a particular disease, preventing its onset and saving lives. For instance, In 1958 763,094 cases of measles were registered leading to 552 deaths in the United States. However, as new vaccines were developed and used, the number of cases dropped to less than 150 per year, informs a Center for Disease Control (CDC) report
Over the years a number of trends put together have rejuvenated the market for vaccines. New vaccines have taken over older vaccines targeting new diseases and therapeutic segments. As a result, the prices of vaccines have moved north. In addition, Governments are going in favor of long-term purchasing contracts for vaccines.Vaccines Industry Overview
The Vaccine Market
The vaccine market is segmented based on their usage as:
- Prophylactic and therapeutic vaccines
- Pediatric and Adult vaccines
- Special needs vaccines viz. seasonal, travel, etc.
- Animal vaccines
At present there are just a few major players present in the vaccine market, as a result the competition is small. However, with time as the competition increases, the vaccine market will resemble the conventional market for pharmaceutical drug
products, some of which are also used in the preparation of medicated skin care products
. As a result, companies would need a fast market entry so as to cash in on the growing market and minimize the threat of competition. Further, an increased manufacturing capacity will be needed to compete effectively. Another challenge will be to bring new products to the market, as these being pharmaceutical products, would require a rigorous review of laboratory and clinical data to ensure their efficacy, purity, safety, and potency.Vaccine Market Size & Growth
The global vaccine market stood at US$ 11.42 billion in 2006, growing at a rate of 16.52%, it is said to touch US$ 21.05 billion by 2010, and up to $23.8 billion by 2012.
The driver of this growth is new product development. While pediatric vaccines have dominated the markets till now, the rise in the use of adult vaccines has increased due to the uptake of hepatitis and influenza vaccines.
- Adult vaccines market is expected to rise to $7.5 billion in 2012. When combined with the pediatric vaccine markets, the total market for vaccines is projected to grow to $15 billion by 2012.
- Influenza vaccines and Hepatitis vaccines, with an estimated growth rate of over 8 percent, are the fastest growing segments within the adult's vaccine market. The flu vaccines growing at 13.2 percent, will top $4 billion by 2012. The Hepatitis vaccines on the other hand are slated to make it to $1.5 billion by 2012.
- The prophylactic vaccine market is forecasted to grow at an annual rate of 9-11 percent. Within the therapeutic vaccines segment, the cancer vaccines market is expected to rise to over $8 billion by 2012.
Vaccine Industry Trends
- The infectious disease vaccine segment, with a growth of about 26%, is growing the fastest. Of all, the influenza, HIV and cancer is expected to witness the maximum growth within market.
- Increasingly, vaccines are being aimed at adolescents and adults, in addition to infants and kids.
- Vaccines to stimulate innate immune responses as well as adaptive are being developed.
- The use of a combination of vaccines is becoming more common. Vaccines comprising 5 or more ingredients are being used in different parts of the world.
- New ways of administering vaccines are under development including skin patches, aerosols via inhalation devices, and consuming biotechnology products such as genetically engineered plants.
- Vaccines aimed at anthrax, plague, and smallpox, are being designed to defend against bioterrorist attacks.
- Curative vaccines targeting chronic infections, which at present require treatment with anti-infective drugs, in addition to preventive vaccines are being designed.
- The growth of the industry will depend on innovations in therapeutic vaccines.
- An increasing number of traditional companies are expected to enter the vaccine market.
- Vaccines for infectious diseases are being recognized as a critical unmet need.
While many life sciences fields have felt the impact of the recessionary economic scene, vaccines market has experienced growth, and is pretty much forecasted to keep up with the trend. At the same time the challenges posed by the 2009 financial crisis
will continue to loom large.